Lyndon Brown

Solubility-Driven Optimization of Phosphodiesterase-4 Inhibitors Leading to a Clinical Candidate

Neil J. Press, Roger Taylor, Joseph D. Fullerton et al. · Journal of Medicinal Chemistry · 2012 · 33 citations · Full text

Medicinal Chemistry, Solubility-driven Optimization, Pharmaceutical Science +13

Discovery of Fevipiprant (NVP-QAW039), a Potent and Selective DP₂ Receptor Antagonist for Treatment of Asthma

David A. Sandham, Lucy Barker, Lyndon Brown et al. · ACS Medicinal Chemistry Letters · 2017 · 31 citations · Full text

Discovery and characterization of NVP-QAV680, a potent and selective CRTh2 receptor antagonist suitable for clinical testing in allergic diseases

David A. Sandham, Nicola Arnold, Heinrich Aschauer et al. · Bioorganic & Medicinal Chemistry · 2013 · 22 citations · Full text

Allergy, Clinical Testing, Medicine +8

Discovery and Optimization of 4-(8-(3-Fluorophenyl)-1,7-naphthyridin-6-yl)transcyclohexanecarboxylic Acid, an Improved PDE4 Inhibitor for the Treatment of Chronic Obstructive Pulmonary Disease (COPD)

Neil J. Press, Roger Taylor, Joseph D. Fullerton et al. · Journal of Medicinal Chemistry · 2015 · 18 citations · Full text

Pde4 Inhibitors, Medicinal Chemistry, Compound 2 +14

The design and synthesis of thrombin inhibitors: analogues of MD805 containing non-polar surrogates for arginine at the P1 position

Urs Baettig, Lyndon Brown, Derek E. Brundish et al. · Bioorganic & Medicinal Chemistry Letters · 2000 · 13 citations · Full text

Non-polar Surrogates, Combinatorial Chemistry, Medicinal Chemistry +12